Joan T Merrill

2 months ago | healio.com | Justin Cooper |Shenaz Bagha |Joan T Merrill

The FDA has accepted an investigational new drug application for ALLO-329, an allogeneic chimeric antigen receptor T-cell therapy that may bypass lymphodepletion, paving the way for a phase 1 trial in lupus and other autoimmune diseases.

Jun 24, 2024 | acrjournals.onlinelibrary.wiley.com | Joan T Merrill |Yoshiya Tanaka |David D'Cruz |Karina Vila-Rivera

Supporting Information Filename Description art42926-sup-0001-Disclosureform.pdfPDF document, 478.5 KB Disclosure Form art42926-sup-0002-Supinfo.pdfPDF document, 3.5 MB Appendix S1: Supporting Information

Nov 16, 2023 | healio.com | Rob Volansky |Shenaz Bagha |Joan T Merrill

You've successfully added Rheumatology: Lupus to your alerts. You will receive an email when new content is published. Click Here to Manage Email Alerts We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected].

Aug 9, 2023 | acrjournals.onlinelibrary.wiley.com | Joan T Merrill |Joel Guthridge |Miles Smith |Joshua June

Full Length This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to differences between this version and the Version of Record. Please cite this article as doi: 10.1002/art.42652.

Jul 25, 2023 | lupus.bmj.com | Elaine Karis |Joan T Merrill |Anca D. Askanase |Sandra Garces

Adaptive design of the phase IIb trials for rozibafusp alfa and efavaleukin alfa in SLEAn adaptive design is being used in two ongoing phase IIb double-blind, placebo-controlled, dose-ranging, multicentre studies at Amgen evaluating the safety and efficacy of rozibafusp alfa (AMG 570) (NCT04058028) and efavaleukin alfa (AMG 592) (NCT04680637).